Is Royalty Pharma (RPRX) Pricing Reflect Its Strong 1 Year Share Price Performance [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
This article focuses squarely on what you might be paying for compared with what you are getting. The stock last closed at US$40.26, with returns of 3.6% over 7 days, 5.2% over 30 days, 3.6% year to date, 40.0% over 1 year, 10.9% over 3 years and a 13.0% decline over 5 years. Recent headlines around Royalty Pharma have mainly focused on its portfolio of drug royalties and how investors view the quality and timing of those cash flows, which helps frame this share price performance. That context matters for valuation because the market is constantly reassessing what those future royalty streams could be worth. On Simply Wall St's 6 point valuation checklist, Royalty Pharma scores 3 out of 6 . We will look at what the standard valuation approaches say about the stock and then finish with a different way of thinking about value that investors often find more useful. Royalty Pharma delivered 40.0% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Royalty Pharma promises $500M to Teva for advancing vitiligo treatment [Seeking Alpha]Seeking Alpha
- Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for VitiligoGlobeNewswire
- Royalty Pharma Announces Dividend IncreaseGlobeNewswire
- Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones [Yahoo! Finance]Yahoo! Finance
RPRX
Sec Filings
- 1/7/26 - Form 144
- 1/6/26 - Form 3
- 1/6/26 - Form 4
- RPRX's page on the SEC website